For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Please note that the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved Paxlovid.
